CEAT Limited Share Price Could Reach Rs 3,800: Anand Rathi Research Suggests BUY Call
Anand Rathi Share and Stock Brokers has issued a Buy recommendation on CEAT Limited with a revised target price of Rs 3,800, highlighting its recent acquisition of Camso as a game-changer. While the acquisition introduces immediate challenges, its long-term potential in the Off-Highway Tire (OHT) segment, along with CEAT's robust domestic market position, sets the stage for sustained growth. This report delves into the financial outlook, strategic benefits, and valuation metrics, offering a comprehensive view for investors.
Acquisition of Camso: A Strategic Leap
CEAT's acquisition of Camso for $225 million (approx. Rs 19 billion) is expected to bolster its footprint in the profitable OHT market. The acquisition includes two Sri Lankan factories, key intellectual properties, and a global distribution network. Post-acquisition, the OHT segment is forecasted to contribute 25-26% to CEAT's revenue by FY27, driven by synergies in the compact construction equipment, agriculture, and premium industrial markets.
Immediate Challenges and Long-Term Potential
Despite the strategic benefits, the acquisition is projected to result in a net loss of Rs 150 million in FY26 due to a muted Original Equipment Manufacturer (OEM) segment and transitional costs. However, a slight profit of Rs 236 million is anticipated by FY27 as margins stabilize and synergies materialize. The EBITDA margin is expected to climb to 17%, reflecting better cost efficiencies and operational scaling.
Market Position and Synergies
CEAT’s strategy hinges on leveraging Camso’s strong brand and established market presence. Key customers, including JCB, CNH, and Kubota, and a network of 200 distributors offer immediate market access. Additionally, Camso’s product portfolio in premium and specialty OHT categories aligns with CEAT's focus on high-margin segments.
Financial Projections and Valuations
Revenue Growth: CEAT’s consolidated revenue is projected to grow at a 9.6% CAGR from FY24 to FY27, driven by domestic and export markets.
Profitability Metrics: EBITDA margins are expected to stabilize at 13.3% by FY27, supported by price hikes and cost reductions.
Target Valuation: The stock’s target price of Rs 3,800 incorporates a valuation of 16x FY27 P/E for the core business and 18x for Camso, reflecting the latter's higher operating margins and return on capital employed (RoCE).
Key Financial Highlights
Year | Revenue (Rs million) | EBITDA Margin (%) | P/E Ratio | EPS (Rs) | Net Debt/Equity |
---|---|---|---|---|---|
FY23 | 1,13,149 | 8.6 | 58.0 | 54.3 | 0.6 |
FY24 | 1,19,435 | 13.8 | 18.2 | 173.3 | 0.4 |
FY25e | 1,30,913 | 11.3 | 22.9 | 137.7 | 0.4 |
FY26e | 1,44,214 | 12.8 | 16.1 | 196.0 | 0.3 |
FY27e | 1,57,453 | 13.3 | 13.6 | 231.4 | 0.3 |
Competitive Landscape and Risks
CEAT faces significant competition in the OHT segment from BKT Tires and Michelin, which dominate the high-margin markets. Additionally, the rising adoption of radialization poses challenges in the bias tire segment. Commodity price volatility and keener competition remain downside risks to CEAT's profitability and market share.
Capex and Debt Dynamics
CEAT's debt-to-equity ratio is expected to increase from 0.5x to 1x post-acquisition, with annual capex requirements of Rs 12.3 billion through FY27. Despite these obligations, the company anticipates an RoCE exceeding 10%, bolstered by its premium product positioning.
Analyst Recommendations
Anand Rathi has maintained a Buy rating on CEAT, citing robust domestic demand, strategic market positioning, and long-term synergies from the Camso acquisition. Investors should consider potential short-term challenges but focus on the strategic merits and value creation.
Actionable Insights for Investors
Short-Term Strategy: Investors may accumulate shares at current levels, given the anticipated improvement in EBITDA margins and market share gains.
Long-Term Perspective: The Camso acquisition's synergies and expanded global footprint provide a compelling growth narrative, justifying the stock's valuation.
Target Price: With a target price of Rs 3,800, the stock offers an attractive upside potential for patient investors.